DK3448419T5 - Interferon-beta-antistoffer og anvendelser deraf - Google Patents

Interferon-beta-antistoffer og anvendelser deraf Download PDF

Info

Publication number: DK3448419T5
Authority: DK; Denmark
Prior art keywords: interferon; beta antibodies; antibodies; beta
Prior art date: 2016-04-29

Application number

DK17733171.7T

Other languages

English (en)

Other versions

DK3448419T3 (da

Inventor

Stefano V Gulla

Christine Huard

Janet Elizabeth Buhlmann

Juan Carlos Almagro

Sreekumar R Kodangattil

Steven A Greenberg

Edward Roland Lavallie

Eric M Bennett

Lidia Mosyak

Jame Perry Hall

Anthony John Coyle

Original Assignee

Pfizer

Brigham & Womens Hospital Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-29

Filing date

2017-04-28

Publication date

2024-09-09

2017-04-28 Application filed by Pfizer, Brigham & Womens Hospital Inc filed Critical Pfizer

2023-06-26 Publication of DK3448419T3 publication Critical patent/DK3448419T3/da

2024-09-09 Application granted granted Critical

2024-09-09 Publication of DK3448419T5 publication Critical patent/DK3448419T5/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

DK17733171.7T 2016-04-29 2017-04-28 Interferon-beta-antistoffer og anvendelser deraf DK3448419T5 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201662329327P	2016-04-29	2016-04-29
US201662339709P	2016-05-20	2016-05-20
US201762483669P	2017-04-10	2017-04-10
PCT/US2017/030089 WO2017189983A1 (en)	2016-04-29	2017-04-28	Interferon beta antibodies and uses thereof

Publications (2)

Publication Number	Publication Date
DK3448419T3 DK3448419T3 (da)	2023-06-26
DK3448419T5 true DK3448419T5 (da)	2024-09-09

Family

ID=59215947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17733171.7T DK3448419T5 (da)	2016-04-29	2017-04-28	Interferon-beta-antistoffer og anvendelser deraf

Country Status (29)

Country	Link
US (3)	US10829553B2 (da)
EP (2)	EP3448419B1 (da)
JP (2)	JP6799076B2 (da)
KR (1)	KR102527840B1 (da)
CN (1)	CN109069606B (da)
AU (1)	AU2017258492B2 (da)
BR (1)	BR112018072118A2 (da)
CA (1)	CA2965652A1 (da)
CO (1)	CO2018012497A2 (da)
DK (1)	DK3448419T5 (da)
ES (1)	ES2950288T3 (da)
FI (1)	FI3448419T3 (da)
HR (1)	HRP20230605T1 (da)
HU (1)	HUE063621T2 (da)
IL (1)	IL262244B2 (da)
MX (1)	MX394513B (da)
MY (1)	MY194084A (da)
NZ (1)	NZ747225A (da)
PE (1)	PE20190371A1 (da)
PH (1)	PH12018502275B1 (da)
PL (1)	PL3448419T3 (da)
PT (1)	PT3448419T (da)
RU (1)	RU2750454C2 (da)
SA (1)	SA518400327B1 (da)
SG (1)	SG11201809456UA (da)
SI (1)	SI3448419T1 (da)
TW (1)	TWI776808B (da)
WO (1)	WO2017189983A1 (da)
ZA (1)	ZA201806682B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX394513B (es)	2016-04-29	2025-03-24	Pfizer	Anticuerpos de interferon beta y usos de los mismos
EP4410378A3 (en)	2016-07-01	2024-10-09	Resolve Therapeutics, LLC	Optimized binuclease fusions and methods
MX2020002070A (es)	2017-08-22	2020-03-24	Sanabio Llc	Receptores solubles de interferon y usos de los mismos.
US20210070871A1 (en)	2018-04-25	2021-03-11	Prometheus Biosciences, Inc.	Optimized anti-tl1a antibodies
CN113728006B (zh) *	2019-01-31	2022-10-14	广东旋玉健康生物科技有限公司	新型抗ifnar1抗体
EP4048309A4 (en)	2019-10-24	2024-02-21	Prometheus Biosciences, Inc.	HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES
CN114733455B (zh) *	2022-04-15	2023-02-14	北京田园奥瑞生物科技有限公司	一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物精子分型的方法
EP4590699A1 (en) *	2022-09-22	2025-07-30	Pfizer Inc.	Methods of treatment with ifn-beta antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4754065A (en)	1984-12-18	1988-06-28	Cetus Corporation	Precursor to nucleic acid probe
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
EP0440686B1 (en) *	1988-10-14	1996-01-03	Berlex Laboratories, Inc.	Peptides representing epitopic sites on r-ifn-beta, antibodies thereto, and uses thereof
US6682896B1 (en) *	1988-10-14	2004-01-27	Schering Aktiengesellschaft	Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL108584A (en)	1994-02-07	2008-03-20	Yeda Res & Dev	Cloning of interferon -alpha/beta binding protein
ZA9811070B (en) *	1997-12-08	2000-07-03	Genentech Inc	Type I interferons.
ES2307832T3 (es)	2001-12-03	2008-12-01	Amgen Fremont Inc.	Clasificacion de anticuerpos basada en las caracteristicas de union.
KR100708398B1 (ko)	2002-03-22	2007-04-18	(주) 에이프로젠	인간화 항체 및 이의 제조방법
PT2263692T (pt)	2002-12-24	2018-11-28	Rinat Neuroscience Corp	Anticorpos anti-ngf e métodos de utilização dos mesmos
BR112013024717A2 (pt)	2011-04-07	2017-08-08	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
CN102898521A (zh) *	2011-07-26	2013-01-30	上海市免疫学研究所	抗β-干扰素单克隆抗体及其应用
US10647756B2 (en)	2015-05-18	2020-05-12	Pfizer Inc.	Humanized antibodies
CA2990662A1 (en)	2015-06-26	2016-12-29	Bioverativ Usa Inc.	Methods of treating autoimmune and alloimmune disorders
MX394513B (es)	2016-04-29	2025-03-24	Pfizer	Anticuerpos de interferon beta y usos de los mismos

2017
- 2017-04-28 MX MX2018013222A patent/MX394513B/es unknown
- 2017-04-28 CA CA2965652A patent/CA2965652A1/en active Pending
- 2017-04-28 IL IL262244A patent/IL262244B2/en unknown
- 2017-04-28 PL PL17733171.7T patent/PL3448419T3/pl unknown
- 2017-04-28 CN CN201780025961.XA patent/CN109069606B/zh active Active
- 2017-04-28 TW TW106114362A patent/TWI776808B/zh active
- 2017-04-28 SI SI201731384T patent/SI3448419T1/sl unknown
- 2017-04-28 RU RU2018141839A patent/RU2750454C2/ru active
- 2017-04-28 HU HUE17733171A patent/HUE063621T2/hu unknown
- 2017-04-28 DK DK17733171.7T patent/DK3448419T5/da active
- 2017-04-28 JP JP2018556490A patent/JP6799076B2/ja active Active
- 2017-04-28 AU AU2017258492A patent/AU2017258492B2/en active Active
- 2017-04-28 KR KR1020187034153A patent/KR102527840B1/ko active Active
- 2017-04-28 MY MYPI2018703975A patent/MY194084A/en unknown
- 2017-04-28 PH PH1/2018/502275A patent/PH12018502275B1/en unknown
- 2017-04-28 BR BR112018072118-2A patent/BR112018072118A2/pt active Search and Examination
- 2017-04-28 US US15/581,079 patent/US10829553B2/en active Active
- 2017-04-28 PT PT177331717T patent/PT3448419T/pt unknown
- 2017-04-28 WO PCT/US2017/030089 patent/WO2017189983A1/en not_active Ceased
- 2017-04-28 EP EP17733171.7A patent/EP3448419B1/en active Active
- 2017-04-28 SG SG11201809456UA patent/SG11201809456UA/en unknown
- 2017-04-28 EP EP23177086.8A patent/EP4273165A3/en active Pending
- 2017-04-28 ES ES17733171T patent/ES2950288T3/es active Active
- 2017-04-28 FI FIEP17733171.7T patent/FI3448419T3/fi active
- 2017-04-28 PE PE2018002056A patent/PE20190371A1/es unknown
- 2017-04-28 HR HRP20230605TT patent/HRP20230605T1/hr unknown
- 2017-04-28 NZ NZ747225A patent/NZ747225A/en unknown
2018
- 2018-10-08 ZA ZA2018/06682A patent/ZA201806682B/en unknown
- 2018-10-28 SA SA518400327A patent/SA518400327B1/ar unknown
- 2018-11-21 CO CONC2018/0012497A patent/CO2018012497A2/es unknown
2020
- 2020-11-09 US US17/092,998 patent/US11858986B2/en active Active
- 2020-11-19 JP JP2020192541A patent/JP7102489B2/ja active Active
2023
- 2023-11-16 US US18/511,744 patent/US12448439B2/en active Active

Also Published As

Publication number	Publication date
MY194084A (en)	2022-11-11
KR102527840B1 (ko)	2023-05-03
CN109069606A (zh)	2018-12-21
SI3448419T1 (sl)	2023-10-30
EP3448419B1 (en)	2023-06-07
US12448439B2 (en)	2025-10-21
RU2018141839A3 (da)	2020-10-16
MX2018013222A (es)	2019-04-22
US11858986B2 (en)	2024-01-02
EP3448419A1 (en)	2019-03-06
JP2021040642A (ja)	2021-03-18
TWI776808B (zh)	2022-09-11
RU2018141839A (ru)	2020-05-29
KR20190003625A (ko)	2019-01-09
DK3448419T3 (da)	2023-06-26
HRP20230605T1 (hr)	2023-09-29
CN109069606B (zh)	2022-07-01
SG11201809456UA (en)	2018-11-29
IL262244B2 (en)	2024-01-01
RU2750454C2 (ru)	2021-06-28
TW201739764A (zh)	2017-11-16
EP4273165A2 (en)	2023-11-08
MX394513B (es)	2025-03-24
PH12018502275A1 (en)	2019-09-09
WO2017189983A1 (en)	2017-11-02
SA518400327B1 (ar)	2022-12-03
PT3448419T (pt)	2023-07-26
EP4273165A3 (en)	2023-12-20
ES2950288T3 (es)	2023-10-06
HUE063621T2 (hu)	2024-01-28
JP6799076B2 (ja)	2020-12-09
US10829553B2 (en)	2020-11-10
BR112018072118A2 (pt)	2019-03-19
IL262244B1 (en)	2023-09-01
PL3448419T3 (pl)	2023-09-04
ZA201806682B (en)	2022-05-25
IL262244A (en)	2018-11-29
US20240174742A1 (en)	2024-05-30
JP7102489B2 (ja)	2022-07-19
NZ747225A (en)	2022-07-29
CO2018012497A2 (es)	2018-12-14
PH12018502275B1 (en)	2024-06-28
AU2017258492A1 (en)	2018-10-25
AU2017258492B2 (en)	2023-12-07
US20210163588A1 (en)	2021-06-03
US20170313769A1 (en)	2017-11-02
FI3448419T3 (fi)	2023-08-02
PE20190371A1 (es)	2019-03-08
JP2019516366A (ja)	2019-06-20
CA2965652A1 (en)	2017-10-29

Publication	Publication Date	Title
DK3625263T3 (da)	2025-06-30	Anti-galectin- 9-antistoffer og anvendelser deraf
DK3383916T3 (da)	2022-03-28	Anti-CD73-antistoffer og anvendelser deraf
IL262095A (en)	2018-11-29	Anti-pacap antibodies and uses thereof
DK3443009T3 (da)	2021-12-13	Anti-tim-3-antistoffer og sammensætninger
DK3458479T3 (da)	2021-02-08	Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3532499T3 (da)	2021-06-28	ANTI-IL-33-antistoffer og anvendelser deraf
DK3448386T3 (da)	2021-04-26	Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3596125T3 (da)	2025-12-22	Anti-PAR2-antistoffer og anvendelser deraf
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3922645T3 (da)	2025-06-16	Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
DK3402821T5 (da)	2024-09-23	Psma-bindende antistof og anvendelser deraf
DK3365368T3 (da)	2023-06-26	Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3229838T3 (da)	2020-10-19	Anti-C10orf54-antistoffer og anvendelser deraf
DK3452463T3 (da)	2021-04-26	Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3126388T3 (da)	2019-07-29	Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3258951T3 (da)	2020-04-06	Anti-pvrig antistoffer og fremgangsmåder for anvendelse
EP3464374C0 (en)	2025-08-06	BAFF-R ANTIBODIES AND USES THEREOF
IL263273A (en)	2018-12-31	Anti-gitr antibodies and uses thereof
DK3463435T3 (da)	2021-11-22	Alpha-synuklein-antistoffer og anvendelser deraf
DK3356558T3 (da)	2022-04-25	Sirs patogenbiomarkører og anvendelser deraf
IL271398A (en)	2020-01-30	Anti-l1-cam antibodies and uses thereof
DK3128005T3 (da)	2021-06-28	Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3448419T5 (da)	2024-09-09	Interferon-beta-antistoffer og anvendelser deraf
EP3672987C0 (en)	2025-04-16	ANTI-APELIN ANTIBODIES AND THEIR USES
DK3265123T3 (da)	2023-01-30	Antistoffer, anvendelser og fremgangsmåder